{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:51:27Z","timestamp":1773787887030,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG061431"],"award-info":[{"award-number":["R21AG061431"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this study, we explored the feasibility of using real-world data (RWD) from a large clinical research network to simulate real-world clinical trials of Alzheimer\u2019s disease (AD). The target trial (i.e., NCT00478205) is a Phase III double-blind, parallel-group trial that compared the 23\u2009mg donepezil sustained release with the 10\u2009mg donepezil immediate release formulation in patients with moderate to severe AD. We followed the target trial\u2019s study protocol to identify the study population, treatment regimen assignments and outcome assessments, and to set up a number of different simulation scenarios and parameters. We considered two main scenarios: (1) a one-arm simulation: simulating a standard-of-care (SOC) arm that can serve as an external control arm; and (2) a two-arm simulation: simulating both intervention and control arms with proper patient matching algorithms for comparative effectiveness analysis. In the two-arm simulation scenario, we used propensity score matching controlling for baseline characteristics to simulate the randomization process. In the two-arm simulation, higher serious adverse event (SAE) rates were observed in the simulated trials than the rates reported in original trial, and a higher SAE rate was observed in the 23\u2009mg arm than in the 10\u2009mg SOC arm. In the one-arm simulation scenario, similar estimates of SAE rates were observed when proportional sampling was used to control demographic variables. In conclusion, trial simulation using RWD is feasible in this example of AD trial in terms of safety evaluation. Trial simulation using RWD could be a valuable tool for post-market comparative effectiveness studies and for informing future trials\u2019 design. Nevertheless, such an approach may be limited, for example, by the availability of RWD that matches the target trials of interest, and further investigations are warranted.<\/jats:p>","DOI":"10.1038\/s41746-021-00452-1","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:03:17Z","timestamp":1620972197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0867","authenticated-orcid":false,"given":"Zhaoyi","family":"Chen","sequence":"first","affiliation":[]},{"given":"Hansi","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-9180","authenticated-orcid":false,"given":"Thomas J.","family":"George","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-5595","authenticated-orcid":false,"given":"Mattia","family":"Prosperi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-1017","authenticated-orcid":false,"given":"William R.","family":"Hogan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3608-0244","authenticated-orcid":false,"given":"Zhe","family":"He","sequence":"additional","affiliation":[]},{"given":"Elizabeth A.","family":"Shenkman","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-9461","authenticated-orcid":false,"given":"Fei","family":"Wang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2238-5429","authenticated-orcid":false,"given":"Jiang","family":"Bian","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2125.2004.02184.x","volume":"58","author":"JK Aronson","year":"2004","unstructured":"Aronson, J. K. What is a clinical trial? Br. J. Clin. Pharmacol. 58, 1\u20133 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1740774515625964","volume":"13","author":"A Sertkaya","year":"2016","unstructured":"Sertkaya, A., Wong, H. H., Jessup, A. & Beleche, T. Key cost drivers of pharmaceutical clinical trials in the United States.Clin. Trials 13, 117\u2013126 (2016).","journal-title":"Clin. Trials"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/nyas.12417","volume":"1313","author":"TJ Scott","year":"2014","unstructured":"Scott, T. J., O\u2019Connor, A. C., Link, A. N. & Beaulieu, T. J. Economic analysis of opportunities to accelerate Alzheimer\u2019s disease research and development. Ann. NY Acad. Sci. 1313, 17\u201334 (2014).","journal-title":"Ann. NY Acad. Sci."},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/clpt.2010.114","volume":"88","author":"N Holford","year":"2010","unstructured":"Holford, N., Ma, S. C. & Ploeger, B. A. Clinical trial simulation: a review. Clin. Pharmacol. Ther. 88, 166\u2013182 (2010).","journal-title":"Clin. Pharmacol. Ther."},{"key":"452_CR5","first-page":"1203","volume":"19","author":"J Gal","year":"2018","unstructured":"Gal, J. et al. Optimizing drug development in oncology by clinical trial simulation: why and how? Brief. Bioinform. 19, 1203\u20131217 (2018).","journal-title":"Brief. Bioinform."},{"key":"452_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.16","volume":"97","author":"K Romero","year":"2015","unstructured":"Romero, K. et al. The future is now: model-based clinical trial design for Alzheimer\u2019s disease. Clin. Pharmacol. Ther. 97, 210\u2013214 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u2013764 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0962280211403603","volume":"22","author":"G Danaei","year":"2013","unstructured":"Danaei, G., Rodr\u00edguez, L. A. G., Cantero, O. F., Logan, R. & Hern\u00e1n, M. A. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat. Methods Med. Res. 22, 70\u201396 (2013).","journal-title":"Stat. Methods Med. Res."},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10654-017-0287-2","volume":"32","author":"X Garcia-Albeniz","year":"2017","unstructured":"Garcia-Albeniz, X., Hsu, J. & Hernan, M. A. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. Eur. J. Epidemiol. 32, 495\u2013500 (2017).","journal-title":"Eur. J. Epidemiol."},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1513\/AnnalsATS.201903-241OC","volume":"16","author":"AJ Admon","year":"2019","unstructured":"Admon, A. J. et al. Emulating a novel clinical trial using existing observational data. predicting results of the PreVent study. Ann. Am. Thorac. Soc. 16, 998\u20131007 (2019).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"452_CR11","first-page":"1601","volume":"2018","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Computable eligibility criteria through ontology-driven data access: a case study of hepatitis C virus trials. AMIA Annu. Symp. Proc. 2018, 1601\u20131610 (2018).","journal-title":"AMIA Annu. Symp. Proc."},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","volume":"6","author":"MA Brookhart","year":"2013","unstructured":"Brookhart, M. A., Wyss, R., Layton, J. B. & St\u00fcrmer, T. Propensity score methods for confounding control in non-experimental. Res. Circ. Cardiovasc. Qual. Outcomes 6, 604\u2013611 (2013).","journal-title":"Res. Circ. Cardiovasc. Qual. Outcomes"},{"key":"452_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2214\/AJR.17.19499","volume":"211","author":"IA Dekkers","year":"2018","unstructured":"Dekkers, I. A. & van der Molen, A. J. Propensity score matching as a substitute for randomized controlled trials on acute kidney injury after contrast media administration: a systematic review. AJR Am. J. Roentgenol. 211, 822\u2013826 (2018).","journal-title":"AJR Am. J. Roentgenol."},{"key":"452_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/pst.1889","volume":"17","author":"J Lin","year":"2018","unstructured":"Lin, J., Gamalo\u2010Siebers, M. & Tiwari, R. Propensity score matched augmented controls in randomized clinical trials: a case study. Pharm. Stat. 17, 629\u2013647 (2018).","journal-title":"Pharm. Stat."},{"key":"452_CR15","unstructured":"Hernan, M. A. & Robins, J. M. Causal Inference: What If (Chapman & Hall\/CRC, Boca Raton, 2020)."},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11121-014-0513-z","volume":"16","author":"EA Stuart","year":"2015","unstructured":"Stuart, E. A., Bradshaw, C. P. & Leaf, P. J. Assessing the generalizability of randomized trial results to target populations. Prev. Sci. 16, 475\u2013485 (2015).","journal-title":"Prev. Sci."},{"key":"452_CR17","first-page":"849","volume":"2017","author":"Z He","year":"2017","unstructured":"He, Z. et al. Comparing and contrasting a priori and a posteriori generalizability assessment of clinical trials on type 2 diabetes mellitus. AMIA Annu. Symp. Proc. 2017, 849\u2013858 (2017).","journal-title":"AMIA Annu. Symp. Proc."},{"key":"452_CR18","doi-asserted-by":"publisher","first-page":"1802218","DOI":"10.1183\/13993003.02218-2018","volume":"52","author":"R Shrimanker","year":"2018","unstructured":"Shrimanker, R., Beasley, R. & Kearns, C. Letting the right one in: evaluating the generalisability of clinical trials.Eur. Respir. J. 52, 1802218 (2018).","journal-title":"Eur. Respir. J."},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/add.13789","volume":"112","author":"R Susukida","year":"2017","unstructured":"Susukida, R., Crum, R.M., Ebnesajjad, C., Stuart, E. & Mojtabai, R. Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.Addiction 112, 1210\u20131219 (2017).","journal-title":"Addiction"},{"key":"452_CR20","first-page":"1101","volume":"2019","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Assessing the validity of a a priori patient-trial generalizability score using real-world data from a large clinical data research network: a colorectal cancer clinical trial case study. AMIA Annu. Symp. Proc. 2019, 1101\u20131110 (2020).","journal-title":"AMIA Annu. Symp. Proc."},{"key":"452_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/CLEP.S242097","volume":"12","author":"K Thorlund","year":"2020","unstructured":"Thorlund, K., Dron, L., Park, J. J. H. & Mills, E. J. Synthetic and external controls in clinical trials \u2013 a primer for researchers. Clin. Epidemiol. 12, 457\u2013467 (2020).","journal-title":"Clin. Epidemiol."},{"key":"452_CR22","doi-asserted-by":"publisher","first-page":"e1086","DOI":"10.1136\/bmj.e1086","volume":"344","author":"LM Schwartz","year":"2012","unstructured":"Schwartz, L. M. & Woloshin, S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ 344, e1086 (2012).","journal-title":"BMJ"},{"key":"452_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","volume":"32","author":"WJ Deardorff","year":"2015","unstructured":"Deardorff, W. J., Feen, E. & Grossberg, G. T. The use of cholinesterase inhibitors across all stages of Alzheimer\u2019s disease. Drugs Aging 32, 537\u2013547 (2015).","journal-title":"Drugs Aging"},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/cns.12076","volume":"19","author":"JL Cummings","year":"2013","unstructured":"Cummings, J. L. et al. High-dose donepezil (23\u2009mg\/day) for the treatment of moderate and severe Alzheimer\u2019s disease: drug profile and clinical guidelines. CNS Neurosci. Ther. 19, 294\u2013301 (2013).","journal-title":"CNS Neurosci. Ther."},{"key":"452_CR25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jamda.2011.02.004","volume":"12","author":"IH Gomolin","year":"2011","unstructured":"Gomolin, I. H., Smith, C. & Jeitner, T. M. Donepezil dosing strategies: pharmaco-kinetic considerations. J. Am. Med. Dir. Assoc. 12, 606\u2013608 (2011).","journal-title":"J. Am. Med. Dir. Assoc"},{"key":"452_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/ane.12386","volume":"131","author":"J-H Lee","year":"2015","unstructured":"Lee, J.-H., Jeong, S.-K., Kim, B. C., Park, K. W. & Dash, A. Donepezil across thespectrum of Alzheimer\u2019s disease: dose optimization and clinical relevance. Acta Neurol. Scand. 131, 259\u2013267 (2015).","journal-title":"Acta Neurol. Scand"},{"key":"452_CR27","doi-asserted-by":"publisher","unstructured":"Ghosh, S., Bian, J., Guo, Y. & Prosperi, M. Deep propensity network using a sparseautoencoder for estimation of treatment effects. Journal of the American MedicalInformatics Association. https:\/\/doi.org\/10.1093\/jamia\/ocaa346 (2021).","DOI":"10.1093\/jamia\/ocaa346"},{"key":"452_CR28","unstructured":"NIH. Comparison of 23 mg donepezil sustained release (SR) to 10 mg donepezilimmediate release (IR) in patients with moderate to severe Alzheimer\u2019s disease. Full text view, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00478205 (2014). Accessed 18 Sept 2020"},{"key":"452_CR29","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","volume":"32","author":"MR Farlow","year":"2010","unstructured":"Farlow, M. R. et al. Effectiveness and tolerability of high-dose (23\u2009mg\/d) versusstandard-dose (10\u2009mg\/d) donepezil in moderate to severe Alzheimer\u2019s disease: a24-week, randomized, double-blind study. Clin. Ther. 32, 1234\u20131251 (2010).","journal-title":"Clin. Ther"},{"key":"452_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.9740\/mhc.n106739","volume":"1","author":"C English","year":"2012","unstructured":"English, C. Donepezil 23 mg: is it more advantageous compared to the original?. Ment. Health Clin. 1, 272\u2013273 (2012).","journal-title":"Ment. Health Clin"},{"key":"452_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/ACM.0000000000002029","volume":"93","author":"E Shenkman","year":"2018","unstructured":"Shenkman, E. et al. OneFlorida Clinical Research Consortium: linking a clinical and translational science institute with a community-based distributive medical education model. Acad. Med. 93, 451\u2013455 (2018).","journal-title":"Acad. Med"},{"key":"452_CR32","unstructured":"PCORnet. PCORnet Common Data Model v5.1 Specification (12 September 2019). https:\/\/pcornet.org\/data-driven-common-model\/ (2019)"},{"key":"452_CR33","unstructured":"FDA. CFR - Code of Federal Regulations Title 21. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.80. Accessed 18 Sept 2020."},{"key":"452_CR34","unstructured":"MedDRA. Welcome to MedDRA. https:\/\/www.meddra.org\/. Accessed 18 Sept 2020."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-021-00452-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-021-00452-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-021-00452-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:52:29Z","timestamp":1670075549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-021-00452-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1038\/s41746-021-00452-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.03.20121491","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2020.08.16.20167577","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}